Sanjay Jayasinghe1,2, Rob Menzies3, Clayton Chiu4,2, Cindy Toms5, Christopher C Blyth6, Vicki Krause7, Peter McIntyre4,2,8. 1. National Centre for Immunisation Research and Surveillance for Vaccine Preventable Diseases, Westmead; sanjay.jayasinghe@health.nsw.gov.au. 2. Discipline of Child and Adolescent Health, University of Sydney, and. 3. School of Public Health and Community Medicine, University of New South Wales, Sydney. 4. National Centre for Immunisation Research and Surveillance for Vaccine Preventable Diseases, Westmead. 5. Office of Health Protection, Australian Government Department of Health, Canberra. 6. Department of Infectious Diseases and Microbiology, Princess Margaret Hospital, School of Paediatrics and Child Health and Telethon Kids Institute, University of Western Australia, Perth. 7. Centre for Disease Control, Department of Health, Darwin, Northern Territory; and. 8. School of Public Health, University of Sydney, Sydney, Australia.
Abstract
BACKGROUND: Australia introduced universal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 2011, uniquely among high-income countries giving doses at 2, 4, and 6 months (3 + 0 schedule). Data on impact of a timely 3 + 0 PCV schedule with high coverage are sparse, with none for PCV13. METHODS: We used national surveillance of invasive pneumococcal disease (IPD) from 2002 for baseline and appropriate later comparison periods to calculate incidence rate ratios (IRRs) by serotype and age using a Poisson model. PCV coverage was assessed from the Australian Childhood Immunisation Register. RESULTS: After 9 years of timely 3-dose PCV coverage of >92%, all-age IPD in Australia almost halved (IRR, 0.53; 95% confidence interval [CI], .50-.57), but differed by PCV era. Reductions in IPD due to vaccine serotypes from PCV7 (IRR, 0.20; CI, .17-.22) were about 2-fold greater than for IPD due to extra serotypes in PCV13 (13v-non7v) in a similar period (IRR, 0.58; CI, .51-.66). Post-PCV13 declines in serotype 19A IPD in persons aged <2 years (IRR, 0.23; CI, .13-.35) and ≥2 years (IRR, 0.35; CI, .28-.44) differed from other 13v-non7v IPD (IRR, 0.73; CI, .35-1.48 for those aged <2 years and IRR, 0.96; CI, .81-1.15 for those ≥2 years). Meningitis due to vaccine serotypes nearly disappeared in children eligible for 3 PCV13 doses. IPD due to non-PCV13 serotypes increased by 30% compared with 76% for non-PCV7 serotypes in equivalent period of vaccine use. CONCLUSIONS: Reductions in vaccine-type IPD post-PCV13 were inferior to Australian experience with PCV7 and reports from high-income countries giving a PCV booster dose. Applicability of findings to other settings would depend on age of IPD onset, serotype profile, and timeliness of vaccination.
BACKGROUND: Australia introduced universal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 2011, uniquely among high-income countries giving doses at 2, 4, and 6 months (3 + 0 schedule). Data on impact of a timely 3 + 0 PCV schedule with high coverage are sparse, with none for PCV13. METHODS: We used national surveillance of invasive pneumococcal disease (IPD) from 2002 for baseline and appropriate later comparison periods to calculate incidence rate ratios (IRRs) by serotype and age using a Poisson model. PCV coverage was assessed from the Australian Childhood Immunisation Register. RESULTS: After 9 years of timely 3-dose PCV coverage of >92%, all-age IPD in Australia almost halved (IRR, 0.53; 95% confidence interval [CI], .50-.57), but differed by PCV era. Reductions in IPD due to vaccine serotypes from PCV7 (IRR, 0.20; CI, .17-.22) were about 2-fold greater than for IPD due to extra serotypes in PCV13 (13v-non7v) in a similar period (IRR, 0.58; CI, .51-.66). Post-PCV13 declines in serotype 19A IPD in persons aged <2 years (IRR, 0.23; CI, .13-.35) and ≥2 years (IRR, 0.35; CI, .28-.44) differed from other 13v-non7v IPD (IRR, 0.73; CI, .35-1.48 for those aged <2 years and IRR, 0.96; CI, .81-1.15 for those ≥2 years). Meningitis due to vaccine serotypes nearly disappeared in children eligible for 3 PCV13 doses. IPD due to non-PCV13 serotypes increased by 30% compared with 76% for non-PCV7 serotypes in equivalent period of vaccine use. CONCLUSIONS: Reductions in vaccine-type IPD post-PCV13 were inferior to Australian experience with PCV7 and reports from high-income countries giving a PCV booster dose. Applicability of findings to other settings would depend on age of IPD onset, serotype profile, and timeliness of vaccination.
Authors: Grant A Mackenzie; Isaac Osei; Rasheed Salaudeen; Ousman Secka; Umberto D'Alessandro; Ed Clarke; Jonas Schmidt-Chanasit; Paul V Licciardi; Cattram Nguyen; Brian Greenwood; Kim Mulholland Journal: Trials Date: 2022-01-15 Impact factor: 2.728
Authors: Grant A Mackenzie; Isaac Osei; Rasheed Salaudeen; Ilias Hossain; Benjamin Young; Ousman Secka; Umberto D'Alessandro; Arto A Palmu; Jukka Jokinen; Jason Hinds; Stefan Flasche; Kim Mulholland; Cattram Nguyen; Brian Greenwood Journal: Trials Date: 2022-01-24 Impact factor: 2.728
Authors: Catherine Hyams; Zahin Amin-Chowdhury; Norman K Fry; Paul North; Adam Finn; Andrew Judge; Shamez N Ladhani; O Martin Williams Journal: Emerg Microbes Infect Date: 2021-12 Impact factor: 7.163
Authors: Todd D Swarthout; Ana Ibarz-Pavon; Gift Kawalazira; George Sinjani; James Chirombo; Andrea Gori; Peter Chalusa; Farouck Bonomali; Roseline Nyirenda; Edwin Bulla; Comfort Brown; Jacquline Msefula; Marjory Banda; Jean Kachala; Charles Mwansambo; Marc Yr Henrion; Stephen B Gordon; Neil French; Robert S Heyderman Journal: BMJ Open Date: 2021-06-17 Impact factor: 2.692
Authors: Jocelyn Chan; Cattram D Nguyen; Jana Y R Lai; Eileen M Dunne; Ross Andrews; Christopher C Blyth; Siddhartha Datta; Kim Fox; Rebecca Ford; Jason Hinds; Sophie La Vincente; Deborah Lehmann; Ruth Lim; Tuya Mungun; Paul N Newton; Rattanaphone Phetsouvanh; Willam S Pomat; Anonh Xeuatvongsa; Claire von Mollendorf; David A B Dance; Catherine Satzke; Kim Muholland; Fiona M Russell Journal: BMJ Open Date: 2018-05-18 Impact factor: 2.692